For the transaction, the shares of the company are transferred to a new company with the investors partly guaranteed against loss.
B-To-V Partners, a Switzerland-based angel network, and UK-based peer Rosetta Capital have invested €30m ($40m) in 13 out of 25 portfolio companies of Karolinska Development, an independent investment company backing the Sweden-based Karolinska Institute medical university. The 13 selected companies are: Akinion Pharmaceuticals, Aprea, Axelar, Biosergen, Clanotech, Dilafor, Dilaforette Holding, inhalation Sciences in Sweden, Neodynamics, Nova…
The rest of this content is only accessible to Global Venturing Subscribers.
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
